SCHEMBL4569895

SCHEMBL4569895

Cc1c(C)c(S(=O)(=O)C(C)C)c(C)c2c1OC(C)(C)C2

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
F2 P00734 1/20 0.33
PLG P00747 1/20 0.33
PLAU P00749 1/20 0.33
ST14 Q9Y5Y6 1/20 0.33
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14519926 0.86 CYP1A2 (0.38) ALDH1A1SMN1; SMN2F2PLGPLAU
SCHEMBL12811732 0.83 HSP90AA1 (0.38) HSP90AA1HSP90AB1ALDH1A1SMN1; SMN2F2
SCHEMBL29793307 0.82 HSP90AA1 (0.37) HSP90AA1HSP90AB1ALDH1A1SMN1; SMN2F2
SCHEMBL29506779 0.82 HSP90AA1 (0.37) HSP90AA1HSP90AB1ALDH1A1SMN1; SMN2F2
SCHEMBL29561615 0.82 HSP90AA1 (0.37) HSP90AA1HSP90AB1ALDH1A1SMN1; SMN2F2
SCHEMBL2477502 0.82 HSP90AA1 (0.37) HSP90AA1HSP90AB1ALDH1A1SMN1; SMN2F2
SCHEMBL4047614 0.82 HSP90AA1 (0.37) HSP90AA1HSP90AB1ALDH1A1SMN1; SMN2F2
SCHEMBL17007494 0.82 HSP90AA1 (0.37) HSP90AA1HSP90AB1ALDH1A1SMN1; SMN2F2
SCHEMBL4569875 0.81 HSP90AA1 (0.37) HSP90AA1HSP90AB1ALDH1A1SMN1; SMN2F2
SCHEMBL4569897 0.79 HSP90AA1 (0.36) HSP90AA1HSP90AB1ALDH1A1SMN1; SMN2F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10988505-B2 Matriptase inhibitors and uses thereof Société de commercialisation des produits de la recherche appliquée SOCPRA Sciences Santé et Humaines s.e.c. (CA) 2021-04-27 US disclosed
US-20120269864-A1 Arginine Derivatives with NP-I Antagonistic Activity GB06/019611.7 THERAPIES LIMITED (GB) 2012-10-25 US disclosed
US-20120201749-A1 NP-1 Antagonists and Their Therapeutic Use GB06/019611.7 THERAPIES LIMITED (GB) 2012-08-09 US disclosed
US-8227606-B2 Arginine derivatives with NP-1 antagonistic activity ARK THERAPEUTICS, LTD. (GB) 2012-07-24 US disclosed
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY GB06/019611.7 THERAPIES LIMITED (GB) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120269864-A1 Arginine Derivatives with NP-I Antagonistic Activity NPFFR1, NPR1, ARG1 HSP90AA1 3628/4885HSP90AB1 3444/4885ALDH1A1 2638/4885
US-20120201749-A1 NP-1 Antagonists and Their Therapeutic Use NPFFR1, NR0B1, NR0B2 HSP90AA1 3509/4885HSP90AB1 2852/4885ALDH1A1 1613/4885
US-10988505-B2 Matriptase inhibitors and uses thereof MMP7, MATR3, TMPRSS15 HSP90AA1 3276/4885HSP90AB1 3012/4885ALDH1A1 1950/4885
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY NPFFR1, NPR1, ARG1 HSP90AA1 3628/4885HSP90AB1 3444/4885ALDH1A1 2638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.